The cost per effectively treated patient was lower with the PCSK9 inhibitor evolocumab compared with alirocumab over a 1-year period, according to analysis presented at the National Lipid Association Scientific Sessions.
Read more at Healio
The cost per effectively treated patient was lower with the PCSK9 inhibitor evolocumab compared with alirocumab over a 1-year period, according to analysis presented at the National Lipid Association Scientific Sessions.
Read more at Healio